PTC Therapeutics PTCT Purchases of intangible assets included in accrued expenses and other liabilities
Purchases of intangible assets included in accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's purchases of intangible assets included in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's purchases of intangible assets included in accrued expenses and other liabilities?
- PTC Therapeutics (PTCT) reported purchases of intangible assets included in accrued expenses and other liabilities of $5.29M in Q1 2026.
- How has PTC Therapeutics's purchases of intangible assets included in accrued expenses and other liabilities changed year-over-year?
- PTC Therapeutics's purchases of intangible assets included in accrued expenses and other liabilities increased by 142.2% year-over-year, from $2.19M to $5.29M.
- What is the long-term trend for PTC Therapeutics's purchases of intangible assets included in accrued expenses and other liabilities?
- Over 2 years (2021 to 2023), PTC Therapeutics's purchases of intangible assets included in accrued expenses and other liabilities has grown at a 56.5% compound annual growth rate (CAGR), from $22.29M to $54.62M.
- What does purchases of intangible assets included in accrued expenses and other liabilities mean?
- Captures the value of intangible assets, such as patents or licenses, acquired through transactions that do not involve immediate cash payments, such as stock-based consideration or deferred liabilities. This metric highlights the company's strategy for expanding its intellectual property portfolio through non-traditional financing. It provides insight into the company's growth strategy and the true cost of asset acquisition beyond cash flow statements.